Cushing’s syndrome is a disorder that occurs when your body makes too much of the hormone cortisol over a long period of time. Cortisol is sometimes called the “stress hormone” because it helps your body respond to stress.
A roundtable on hypercortisolism perspectives recently sponsored by Corcept Therapeutics highlights diagnosis and management in community and academic settings. A group of leading clinicians and educators offer their experiences and views in this fascinating article. Key
This is a series of urgent clinical guidance documents on the management of endocrine conditions in the time of COVID-19. This clinical guidance document underwent expedited open peer review by Jérôme Bertherat (Paris, France), André
In this podcast, Dr. Lewis Blevins discusses a new drug for Cushing’s disease recently approved in the US.
We caught up with Dr. Kevin Yuen, medical director of the Barrow Pituitary Center and the Barrow Neuroendocrinology Clinic in Phoenix, Arizona, and Dr. Lewis Blevins Medical Director of the California Center for Pituitary Disorders at
This article on Cushing’s disease provides a concise, excellent overview of the optimal management and highlights of both surgical and medical advances. Click here to read the article. There are also helpful links to resources
From the Desk of Leslie Edwin, President of CSRF and PWN Contributor – We have just completed an intimate, four-video series of first-hand accounts of the Cushing’s journey. They can be found, along with recorded sessions
This is the first in a series of 6 podcasts on the ins and outs of drug development. In it, we discuss the journey that a promising molecule takes to develop into a life-saving medication and
The CSRF has published materials from their recent Patient Journey Summit,”Defining the New Normal” The topics for the conference, held October 4-6, 2019 at Emory Conference Center Hotel in Atlanta, were organized by a patient-led group. The group
The World Alliance of Pituitary Organizations (WAPO) will participate in the upcoming Cushing’s Support and Research Foundation (CSRF) conference slated for October 4 to 6 in Atlanta, Georgia. Muriel Marks, WAPO’s Executive Director, will present
In a press release, Strongbridge Biopharma announced comprehensive positive results of their Phase 3 SONICS study of RECORLEVTM (levoketoconazole) for the potential treatment of endogenous Cushing’s syndrome. The results were published online in The Lancet
Our podcast today is on silent pituitary adenomas. This is a fascinating look into these tumors that are thought not to secrete hormones. In the podcast Dr. Blevins discusses the complexities and challenges when dealing
Why is it important to know about the symptoms of hypercortisolism and its clinical consequences? And why is early detection so critical? The answers to these vital questions are highlighted in a new web resource
In this podcast, Dr. Blevins reviews a study conducted at the Ludwig Maximilian University of Munich, Germany on pituitary tumor therapeutics and the treatment for tumors that produce ACTH and cause Cushing’s. Dr. Blevins reviews